RxDoctor Payments Data

Etai Goldenberg, MD

Urology · St. Louis, MONPI 1669663605

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $73,032 of the $94,503 with a category attached, or 77.3%. 38 manufacturers reported payments, led by Antares Pharma, Inc. at 54.4% of the total. Reporting peaked in 2023 at $35,685 and has fallen 65.0% since, to $12,478 in 2025. Among urology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$94,503in general payments, 2019–2025

Across 468 payments — averaging $201.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$51K
  • Endo Pharmaceuticals Inc.$25K
  • Endo USA, Inc.$9K
  • Boston Scientific$5K
  • Johnson & Johnson$411
  • Calyxo, Inc.$407
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$4400%
  • Speaking & faculty fees$73,03277%
  • Travel & lodging$9,52810%
  • Food & beverage$11,36712%
  • Education$1350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,503 in reported general payments places this provider in the 95th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$249,643
Medicare patients
433
Services billed
4,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron58$55,167
MyrbetriqMirabegron44$39,524
XyostedTestosterone Enanthate30$24,415
Mirabegron ErMirabegron12$7,992
Testosterone31$7,103
Testosterone Cypionate118$3,743
Tamsulosin Hcl169$2,323
Finasteride134$1,626
Solifenacin Succinate36$1,443
Tadalafil21$1,351
Oxybutynin Chloride ErOxybutynin Chloride38$782
Alfuzosin Hcl ErAlfuzosin Hcl18$524
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$286
Sildenafil Citrate41$211
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim50$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$50$55,16758 claims
Astellas Pharma US IncMyrbetriq$265$39,52444 claims
Antares Pharma, Inc.Xyosted$51,426$24,41530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 urology providers in Missouri.

Other urology in St. Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →